Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Phase II Data Evaluating Clinical Benefit of Revlimid Plus Rituximab for Patients with Untreated Indolent B-Cell Lymphomas Presented at International Conference on Malignant Lymphoma
Phase II Data Evaluating Clinical Benefit of Revlimid Plus Rituximab for Patients with Untreated Indolent B-Cell Lymphomas Presented at International Conference on Malignant Lymphoma
Phase II Data Evaluating Clinical Benefit of Revlimid Plus Rituximab for Patients with Untreated Indolent B-Cell Lymphomas Presented at International Conference on Malignant Lymphoma
Submitted by
admin
on June 18, 2011 - 10:00am
Source:
Yahoo/BusinessWire
News Tags:
Revlimid
lymphoma
rituximab
Headline:
Phase II Data Evaluating Clinical Benefit of Revlimid Plus Rituximab for Patients with Untreated Indolent B-Cell Lymphomas Presented at International Conference on Malignant Lymphoma
Do Not Allow Advertisers to Use My Personal information
